Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
Treatments studied
Part of Cancer clinical trials.
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has come back or spread to 5 or fewer spots (oligometastases) that can be treated with focused radiation (SBRT).
- Your original tumor has been treated and is under control.
- You have a tumor sample that tested positive for EGFR protein.
- You are in good overall health (ECOG score 0 or 1) and expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
This trial tests a targeted therapy (Befotertinib) combined with radiation for people with a specific EGFR mutation whose lung cancer has spread to a few spots. It aims to see if ctDNA monitoring can guide treatment.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This observational study follows people with rare solid tumors and a limited number of metastases treated with a focused radiation technique (SBRT). Doctors want to see outcomes after using a strong, curative-intent radiation dose to all active spots.
This trial tests a combination of a targeted antibody (cetuximab beta) with a type of radiation and immunotherapy for people with advanced solid tumors that have the EGFR protein. It is for patients who have tried other treatments without success.
Hear when a new Oligo-metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.